XPE conducted and managed a Phase IV study for a global pharmaceutical company, collecting data on treatment benefit that earned the client his governmental reimbursement.
The client in question developed a blood cancer treatment. The government can decide to reimburse such new treatments for a period of three years but, in order to be applicable for this system, the client had to collect data on treatment benefits from the Belgian population. As the client’s local affiliation lacked the necessary resources and expertise, they needed an outsourcing partner who could conduct an observational study. Enter XPE Pharma & Science.
Experienced XPE employees designed a Phase IV observational study. In collaboration with the client, a team of medical writers developed the study protocol and the necessary forms, while an IT team built an electronic platform to ensure accurate data collection. XPE Pharma & Science secured approval from local ethics committees, and trained and monitored study staff to optimise data quality. Statistical analyses and a thorough study report followed the data collection process.
XPE provided a tailor-made solution integrating all the aspects required to complete the project. A team of experienced professionals handled the Phase IV study from beginning to end, ensuring data quality and delivery.